Passage Bio to Participate in Upcoming June Investor Conferences
Passage Bio (NASDAQ: PASG) announced its participation in two virtual investor conferences in June 2021. The Jefferies Healthcare Conference will take place on June 2 at 4:30 p.m. ET, featuring a presentation format. On June 10, Passage Bio will engage in a fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference at 11:20 a.m. ET. Both events will be available via live webcast on the company's website, with replays accessible for 30 days post-event. As a clinical-stage genetic medicines firm, Passage Bio focuses on innovative therapies for rare CNS disorders.
- None.
- None.
PHILADELPHIA, May 26, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that management will participate in two upcoming virtual investor conferences in June:
Jefferies Healthcare Conference
Format: Presentation
Date: Wednesday, June 2, 2021
Time: 4:30 p.m. ET
Goldman Sachs 42nd Annual Global Healthcare Conference
Format: Fireside chat
Date: Thursday, June 10, 2021
Time: 11:20 a.m. ET
A live webcast of the events will be available on the Investors & Media section of Passage Bio’s website at investors.passagebio.com. A replay of the presentations will be available for 30 days following the events.
About Passage Bio
At Passage Bio (Nasdaq: PASG), we are on a mission to provide life-transforming gene therapies for patients with rare, monogenic CNS diseases that replace their suffering with boundless possibility, all while building lasting relationships with the communities we serve. Based in Philadelphia, PA, our company has established a strategic collaboration and licensing agreement with the renowned University of Pennsylvania’s Gene Therapy Program to conduct our discovery and IND-enabling preclinical work. This provides our team with enhanced access to a broad portfolio of gene therapy candidates and future gene therapy innovations that we then pair with our deep clinical, regulatory, manufacturing and commercial expertise to rapidly advance our robust pipeline of optimized gene therapies into clinical testing. As we work with speed and tenacity, we are always mindful of patients who may be able to benefit from our therapies. More information is available at www.passagebio.com.
For further information, please contact:
Investors:
Stuart Henderson
Passage Bio
267.866.0114
shenderson@passagebio.com
Media:
Gwen Fisher
Passage Bio
215.407.1548
gfisher@passagebio.com
FAQ
What are the details of Passage Bio's participation in the Jefferies Healthcare Conference?
When is the Goldman Sachs 42nd Annual Global Healthcare Conference featuring Passage Bio?
Will the presentations from the investor conferences be available for replay?
What is Passage Bio's main focus as a company?
How can I access the live webcasts of the Passage Bio conferences?
